Key takeaways
- A Danish cohort study of over 157,000 patients found that 49% of Wegovy users stopped treatment within 12 months.
- One in four patients who discontinued treatment restarted semaglutide therapy within three months, indicating temporary pauses.
- Discontinuation rates were higher among younger patients, men, low-income individuals, and those with prior psychiatric or gastrointestinal drug use.
- The findings highlight major barriers to long-term GLP-1 adherence, particularly financial costs and medication side effects.
What happened
A comprehensive nationwide study of 157,822 adults published in JAMA Network Open has revealed that 49% of patients initiating semaglutide (Wegovy) for obesity discontinued their treatment within 12 months. Led by Aurélie Mailhac, MSc, of Aarhus University Hospital in Denmark, the real-world study defined discontinuation as a prescription gap of 60 days or more. However, the data also showed a notable circular pattern: one in four patients who stopped treatment restarted therapy within three months.
Why it matters
This study highlights a major challenge for the US GLP-1 and medical weight-loss market: high dropout rates driven by cost barriers and side effects. For patients navigating the telehealth landscape, the high attrition rate underscores that starting a GLP-1 is rarely a simple, linear journey. Many patients encounter financial hurdles, struggle with gastrointestinal tolerance, or choose to pause and restart treatment.
Because GLP-1 medications are designed for long-term chronic weight management, stopping treatment prematurely can lead to rapid weight regain. Understanding who is most likely to stop—and why—can help telehealth buyers prepare for the physical and financial realities of these medications before paying out of pocket.
What the data says
The Danish cohort study tracked first-time semaglutide users without diabetes between December 2022 and November 2024. The data shows a steady, cumulative climb in discontinuation rates over the first year of therapy:
- By 3 months: 13% of patients discontinued.
- By 6 months: 27% of patients discontinued.
- By 9 months: 39% of patients discontinued.
- By 12 months: 49% of patients discontinued.
Adjusting the timeline definition shifted these numbers: using a stricter 30-day prescription gap pushed the one-year dropout rate to 58%, while a more lenient 90-day gap lowered it to 45%.
The researchers identified several patient groups with a higher risk of stopping treatment early:
- Socioeconomics: Patients living in low-income municipalities had an 11% higher risk of stopping than those in high-income areas.
- Age and Gender: Younger patients (ages 18 to 29) had a 49% higher risk of stopping compared to older adults (ages 45 to 59), while men carried a 16% higher risk than women.
- Prior Health Factors: Patients with prior use of psychiatric medications (13% higher risk) or gastrointestinal medications (10% higher risk) were more likely to quit. Patients with kidney disease (9% higher risk) or cardiovascular disease (8% higher risk) also saw elevated discontinuation rates.
Very few patients who stopped semaglutide transitioned to alternative brand-name anti-obesity medications. Only 1.4% switched to liraglutide (Saxenda) and just 0.7% switched to tirzepatide (Zepbound). Instead, 25% of those who stopped simply restarted semaglutide within 90 days. The researchers noted this likely points to temporary treatment interruptions or "self-adjusted dosing" beneath recommended guidelines.
How it compares
While the Danish study outlines a 49% dropout rate in a country with universal healthcare, US real-world data paints an even tougher picture. According to the study authors, US-based research has shown first-year GLP-1 discontinuation rates as high as 60%.
The primary difference lies in the financial architecture of US healthcare. In the US, brand-name Wegovy carries a list price of roughly $1,350 per month. If a patient's insurance does not cover weight-loss medications, they face massive out-of-pocket expenses.
This financial steepness is driving many US buyers away from commercial insurance channels and toward online platforms. Many patients utilize the CompareRx provider directory to find and compare more affordable alternatives. For instance, while brand-name Wegovy can cost upwards of $1,000 monthly, compounded semaglutide through telehealth providers frequently ranges from $150 to $300 per month, significantly lowering the financial barrier that causes many to discontinue treatment.
How this fits the bigger picture
The high dropout rate linked to socioeconomics and medication side effects highlights why customized telehealth care has become so popular in the US. When patients struggle with the escalating doses of standard titration schedules, they frequently turn to alternative strategies.
For example, we previously analyzed how a significant portion of patients are taking matters into their own hands; a prior survey revealed 15% of GLP-1 users are microdosing to actively bypass standard doses, manage severe GLP-1 side effects, and stretch their financial budgets.
Furthermore, the high discontinuation rate among lower-income individuals directly correlates with the ongoing restriction of insurance coverage in the US. As detailed in our report on how 14% of employers plan to cut GLP-1 coverage, US patients are increasingly losing their commercial insurance benefits. When employer coverage is dropped, patients are forced to pay cash. This financial shock is a primary driver of the real-world discontinuation rates highlighted in the Danish study.
For those who struggle to see results before dropping out, looking into why some patients face a lack of weight loss on Wegovy can help troubleshoot whether a slower titration or a switch to semaglutide vs tirzepatide is the right medical path.
What happens next
This real-world study emphasizes that prescribing a drug is only the first step. To improve long-term adherence, clinical experts suggest that telehealth providers must offer more robust upfront consultations. This includes discussing long-term costs before writing a prescription, preparing patients for potential gastrointestinal side effects, and offering structured lifestyle support.
As the US market continues to evolve, clinical trials are ongoing for next-generation weight-loss drugs and oral alternatives. These pipeline developments aim to offer easier administration and fewer side effects, which may eventually help bring down the high real-world dropout rates observed with today's injectable therapies.
Disclaimer: CompareRx does not provide medical advice. Always consult with a licensed healthcare professional before starting, stopping, or adjusting any medication.